Alkermes plc. Business Acquisition, Transaction Costs
Alkermes plc. (ALKS) had Business Acquisition, Transaction Costs of $10.00 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes
us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts · last filed 2026-02-25
- 2025-12-31: Business Acquisition, Transaction Costs $10.00M.
| Period end | Business Acquisition, Transaction Costs |
|---|---|
| 2025-12-31 | $10.00M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |